The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.

Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in ...

BURLINGTON, Mass.--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that the Life Science business of Merck KGaA, Darmstadt, ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and ...

Merck KGaA made its largest acquisition in a decade in April 2025 when it snapped up Connecticut rare disease specialist ...

FRANKFURT (Reuters) -Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially ...

Shareholders appeared unconcerned with Merck KGaA's (ETR:MRK) lackluster earnings report last week. We did some digging, and we believe the earnings are stronger than they seem. We've found 21 US ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor. The update provides a closer look at the hand Merck is holding as it gears ...

Merck KGaA (ETR:MRK) reported what executives described as a "solid start" to 2026, with organic growth in its Life Science ...

Two months after saying it was in advanced talks to acquire SpringWorks Therapeutics, Merck KGaA, Darmstadt, Germany, has announced it agreed to purchase the developer of drugs for severe rare disease ...

The registrar ultimately concluded that the competing trademarks were “overall, dissimilar”. Read more at straitstimes.com.